Tous Actualités
Suivre
Abonner Helsinn Healthcare SA

Helsinn Healthcare SA

Helsinn partners with EISAI for Gelclair in Italy

Lugano (ots)

The Swiss pharmaceutical group Helsinn and Eisai
Italy, subsidiary of the Japanese pharmaceutical company, have signed
a licensing agreement for the commercialization of the medical device
Gelclair in Italy.
Helsinn is the worldwide licensor of Gelclair, a viscous, 
concentrated, bioadherent oral gel with a mechanical protective 
action, which relieves pain by adhering to the mucosal surface of the
mouth. By this action, it soothes mucositis and stomatitis oral 
lesions caused by radio and chemotherapy. Oral mucositis can be a 
very impairing condition, as it may interfere with the ability to eat
and drink. Gelclair offers patients an effective and fast symptomatic
relief from painful symptoms. An effective control of such symptoms 
is still an unmet need for cancer patients undergoing radio and 
chemotherapy and Gelclair is one of the very few specific products 
available at present in this setting. It is currently accessible in 
35 countries and over 1 million doses were sold in 2008 worldwide.
"Helsinn is a pharmaceutical group that is focusing in particular 
in Cancer Supportive Care, where we already are partnering with Eisai
for the marketing in the US of our leading pharmaceutical product 
palonosetron", commented Riccardo Braglia, Helsinn's Chief Executive 
Officer. "This further deal with Eisai in Italy reinforces Helsinn's 
commitment to make its innovative products available worldwide to 
grant patients a valid therapeutic option and improve their quality 
of life. We are confident that Eisai, as a first-rate partner, will 
make Gelclair a first-choice product for oral mucositis in Italy", he
concluded  "Eisai is a global pharmaceutical Company with Corporate 
Head Quarters in Japan. The Italian subsidiary focuses its interests 
on the following therapeutic areas: oncology, chronic pain 
management, epilepsy and acid related disorders. The licensing 
agreement with Helsinn group on Gelclair commercialization in Italy 
fits perfectly with our specific commitment to the Oncology field", 
commented Franco Merckling, Eisai s.r.l. Italy Managing Director. "We
strongly believe in this innovative product able to have a positive 
impact on patients' quality of life, avoiding major oral discomfort 
consequent to chemotherapy and radiotherapy treatments. Eisai has a 
long historical experience in patients care, a credo for each Eisai 
employee. We will be able to propose to Italian oncologists Gelclair,
in a new sachet formulation, starting from September this year".
Further information on Gelclair and oral mucositis can be found at
www.gelclair.net
About Helsinn Group
Helsinn is a privately owned pharmaceutical group with 
headquarters in Lugano, Switzerland, and subsidiaries in Ireland and 
USA. Helsinn is the worldwide licensor of Gelclair. Helsinn's unique 
business model is focused on the licensing of pharmaceuticals and 
medical devices in therapeutic niche areas. The Group in-licenses 
early stage new chemical entities, completes their development from 
the performance of pre-clinical/clinical studies and Chemistry, 
Manufacturing and Control (CMC) development, to the filing for and 
attainment of their market approval worldwide. Helsinn's products are
sold directly, through the Group subsidiaries, or eventually 
out-licensed to its network of local marketing and commercial 
partners, selected for their deep in-market knowledge and know-how, 
and assisted and supported with a full range of product and 
scientific management services, including commercial, regulatory, 
financial, legal and medical marketing advice.
The active pharmaceutical ingredients and the finished dosage 
forms are manufactured at Helsinn's cGMP facilities in Switzerland 
and Ireland, and supplied worldwide to its customers. For more 
information about Helsinn Group, please visit the website: 
www.helsinn.com
About EISAI globally
Eisai is one of the world's leading research-based pharmaceutical 
companies. Established in 1941 and headquartered in Tokyo, Japan, we 
employ nearly 11,000 people globally. Eisai has been operating in 
Europe for more than 20 years and our products are available 
throughout the region. As a hub for managing our business, the 
European Knowledge Centre (EKC) plays an important role in leading 
and supporting our operations across Europe. Throughout the world, we
strive to generate customer joy. Driven by our mission of human 
health care (hhc), we aim to understand the priorities of patients 
and their families. That understanding enables us to respond with 
products, information and services to improve their quality of life.
As well as striving to discover new and innovative medicines that 
satisfy unmet medical needs, we focus on ensuring a stable supply of 
high quality products and providing information on their safe and 
proper use. www.eisai.it

Contact:

Helsinn Healthcare SA
Paolo Ferrari, Head of International Marketing
Tel.: +41/91/985'21'21
E-Mail: info-hhc@helsinn.com

Eisai s.r.l.
Paolo Sala, Marketing Director
Tel.: +39/02/5181401
E-Mail: info@eisai.it

Plus de actualités: Helsinn Healthcare SA
Plus de actualités: Helsinn Healthcare SA